September 11, 2020
Norwegian Decision Forum for New Methods on August 31, 2020
On August 31, 2020, Decision Forum for New Methods conducted, and protocol with decisions was published. The meeting considered six drugs and one IVD test.

Five (5) decisions on introduction were made:

  • Abemaciclib (Verzenios) in combination with fulvestrant may be introduced for the treatment of hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer from September 01, 2020
  • Trastuzumabemtansine (Kadcyla) in adjuvant monotherapy treatment of HER2-positive early breast cancer in patients with invasive residual breast disease and/or lymph nodes after neoadjuvant taxane-based and HER2-directed treatment from September 01, 2020
  • Apalutamide (Erleada) may be introduced for the treatment of castration-resistant non-metastatic prostate cancer (nmCRPC) from October 01, 2020
  • Pembrolizumab (Keytruda), in combination with axitinib (Inlyta), may be introduced for the first-line treatment of advanced or metastatic renal cell carcinoma. For the patient group with a good prognosis/favorable risk profile, the treatment can be used from September 01, 2020. For patients with intermediate or high risk, the treatment can be used from the next tender, which is being prepared
  • Upadacitinib (Rinvoq) may be introduced for the treatment of moderate to severe rheumatoid arthritis. The drug should be included in the tender and may be used from February 01, 2021

Two (2) non-introduction decisions were made:

  • Avelumab (Bavencio), in combination with axitinib (Inlyta), is not introduced for the treatment of advanced renal cell carcinoma (RCC). There is significant uncertainty associated with the long-term survival with this treatment, and the price is too high and is not in reasonable proportion to the clinical effect
  • A blood test for preeclampsia in pregnant women is not introduced now. The method evaluation by the National Institute of Public Health shows a lack of documentation of the usefulness of this type of test. The added value of using these tests in clinical practice is therefore uncertain, and there is thus a need for more studies. The Decision Forum for New Methods asks the subject directors to make a new assessment within one year based on updated knowledge

See the full details in Norwegian here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Subscribe to newsletter
Subscribe to our newsletter to get regular updates from us on the changes of reimbursement systems (>100 reimbursement stakeholders in 12 EU countries)